Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Third

Commercialization of Molecular Diagnostics

Addressing Challenges and Fostering Investment in Innovative Diagnostics

February 23-24, 2017 | Moscone South Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

Regulatory hurdles, reimbursement, and market strategy are three main obstacles that must be overcome on the road to commercializing a diagnostic. While traditional business models for bringing diagnostics to market still work, market changes make success difficult for developers, marketers, and investors. Significant limitations remain in the ability of conventional molecular diagnostic technologies to serve the clinical and commercial requirements of the field. At this year's Commercialization of Molecular Diagnostics symposium, experts in product development and launch will come together to provide case studies and lessons learned from their experiences to achieve market success.

Who should attend: Vice Presidents, CEOs, CTOs, Directors, Managers, Researchers, and Scientists from Pharma, Biotech, and healthcare organizations working in business development, molecular diagnostics, and personalized medicine.

Topics may include, but are not limited to:

  • Economics of product development
  • Commercializing companion diagnostics
  • Companion diagnostics for immuno-oncology products
  • Implementing next-generation sequencing
  • Understanding clinical workflow
  • Picking the right product
  • Updates on LDTs – where regulators are headed
  • Reimbursement
  • Managing KOLs and patient advocacy groups

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 15, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Samantha Drinkwater
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: sdrinkwater@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com